Literature DB >> 27115761

An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients.

Yong-Kang Liu1, Bao-Shan Hu2, Zhong-Liang Li2, Xu He3, Yong Li3, Li-Gong Lu4.   

Abstract

PURPOSE: We adopted a new strategy to explore the relationship between the EMT process of CTCs and hepatocellular carcinoma (HCC). Furthermore, we intend to illustrate the potential diagnostic value of CTCs of distinct phenotypes in HCC.
METHODS: The clinical data of 33 HCC patients and 10 healthy volunteers were collected retrospectively. By using the optimized CanPatrol CTC enrichment technique, patient blood samples of about 5 ml were collected, and CTCs were identified and characterized. The first step of this detection process was to isolate CTCs via a filter-based method; then, an RNA in situ hybridization (RNA-ISH) technique based on the branched DNA signal amplification technology was used to classify the CTCs according to EMT markers. The relationships between HCC CTCs and clinical characteristics were analyzed.
RESULTS: The number of epithelial CTCs was related to tumor size (r = 0.456, p = 0.008), epithelial-mesenchymal-mixed CTCs were related to tumor number (r = 0.421, p = 0.015), and mesenchymal CTC was associated with metastasis (r = 0.375, p = 0.032). There was no significant correlation between CTC number and other clinicopathological factors, such as age, serum AFP level or cirrhosis.
CONCLUSIONS: Epithelial-mesenchymal-mixed CTCs seem to play an important role in EMT transition in HCC, mixed CTCs might be a vital factor for intrahepatic metastasis, and mesenchymal CTCs had the potential to be a predictor of extrahepatic metastasis.

Entities:  

Keywords:  Circulating tumor cells; Epithelial-mesenchymal transition; Hepatocellular carcinoma; Metastasis

Mesh:

Substances:

Year:  2016        PMID: 27115761     DOI: 10.1007/s12072-016-9732-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  30 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions.

Authors:  Shiyang Wu; Zhiming Liu; Suyan Liu; Li Lin; Weiwei Yang; Jiasen Xu
Journal:  Clin Chem Lab Med       Date:  2014-02       Impact factor: 3.694

Review 3.  EMT: when epithelial cells decide to become mesenchymal-like cells.

Authors:  Raghu Kalluri
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

4.  Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP(-/-)Vim(-/-) mice.

Authors:  Asa Larsson; Ulrika Wilhelmsson; Marcela Pekna; Milos Pekny
Journal:  Neurochem Res       Date:  2004-11       Impact factor: 3.996

5.  EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.

Authors:  Walid A Osta; Yian Chen; Kaidi Mikhitarian; Michael Mitas; Mohamed Salem; Yusuf A Hannun; David J Cole; William E Gillanders
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

Review 6.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

7.  Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.

Authors:  Tobias M Gorges; Ingeborg Tinhofer; Michael Drosch; Lars Röse; Thomas M Zollner; Thomas Krahn; Oliver von Ahsen
Journal:  BMC Cancer       Date:  2012-05-16       Impact factor: 4.430

8.  Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.

Authors:  Mario Giuliano; Antonio Giordano; Summer Jackson; Kenneth R Hess; Ugo De Giorgi; Michal Mego; Beverly C Handy; Naoto T Ueno; Ricardo H Alvarez; Michelino De Laurentiis; Sabino De Placido; Vicente Valero; Gabriel N Hortobagyi; James M Reuben; Massimo Cristofanilli
Journal:  Breast Cancer Res       Date:  2011-06-15       Impact factor: 6.466

9.  Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer.

Authors:  M Craig Miller; Gerald V Doyle; Leon W M M Terstappen
Journal:  J Oncol       Date:  2009-12-09       Impact factor: 4.375

10.  Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.

Authors:  Glenn Deng; Michael Herrler; David Burgess; Edward Manna; David Krag; Julian F Burke
Journal:  Breast Cancer Res       Date:  2008-08-07       Impact factor: 6.466

View more
  33 in total

1.  Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma.

Authors:  Yuan Cheng; Lei Luo; Juqiang Zhang; Mantian Zhou; Yujun Tang; Guolin He; Yishi Lu; Zhong Wang; MingXin Pan
Journal:  J Gastrointest Surg       Date:  2019-02-25       Impact factor: 3.452

Review 2.  Epithelial-mesenchymal plasticity in circulating tumor cells.

Authors:  Catherine Alix-Panabières; Sonja Mader; Klaus Pantel
Journal:  J Mol Med (Berl)       Date:  2016-12-24       Impact factor: 4.599

Review 3.  What is the optimal surgical treatment for hepatocellular carcinoma beyond the debate between anatomical versus non-anatomical resection?

Authors:  Naoya Sato; Shigeru Marubashi
Journal:  Surg Today       Date:  2021-08-14       Impact factor: 2.549

4.  Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition: Influence on Prognosis in Cytokeratin 19-Positive Hepatocellular Carcinoma.

Authors:  Qian Zhang; Wanting Xing; Jie Zhang; Junwen Hu; Lunan Qi; Bangde Xiang
Journal:  Onco Targets Ther       Date:  2021-03-02       Impact factor: 4.147

Review 5.  Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review.

Authors:  Xu-Rui Jin; Lu-Yao Zhu; Kai Qian; Yong-Geng Feng; Jing-Hai Zhou; Ru-Wen Wang; Li Bai; Bo Deng; Naixin Liang; Qun-You Tan
Journal:  Oncotarget       Date:  2017-04-04

6.  Association of Preoperative NANOG-Positive Circulating Tumor Cell Levels With Recurrence of Hepatocellular Carcinoma.

Authors:  Yongrong Lei; Xishu Wang; Heng Sun; Yuna Fu; Yichen Tian; Ludi Yang; Jianhua Wang; Feng Xia
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

Review 7.  The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells.

Authors:  Alexandra C Kölbl; Udo Jeschke; Ulrich Andergassen
Journal:  Int J Mol Sci       Date:  2016-08-11       Impact factor: 5.923

Review 8.  Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications.

Authors:  Xiao-Xiang Jie; Xiao-Yan Zhang; Cong-Jian Xu
Journal:  Oncotarget       Date:  2017-05-26

9.  Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood.

Authors:  Zhong Wang; Lei Luo; Yuan Cheng; Guolin He; Bangjian Peng; Yi Gao; Ze-Sheng Jiang; MingXin Pan
Journal:  J Gastrointest Surg       Date:  2017-11-20       Impact factor: 3.452

10.  Artificial Intelligence Based on Blood Biomarkers Including CTCs Predicts Outcomes in Epithelial Ovarian Cancer: A Prospective Study.

Authors:  Jun Ma; Jiani Yang; Yue Jin; Shanshan Cheng; Shan Huang; Nan Zhang; Yu Wang
Journal:  Onco Targets Ther       Date:  2021-05-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.